JENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple investor conferences in June and July 2025.
JENA, Germany, May 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the three months ended March 31, 2025, and provided a business update.
JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned.
7 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
6 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | - EPS |
8 Aug 2024 Date | | - Cons. EPS | - EPS |
8 May 2024 Date | | - Cons. EPS | - EPS |
7 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
6 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | - EPS |
8 Aug 2024 Date | | - Cons. EPS | - EPS |
8 May 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Niels C. Riedemann CEO | XSTU Exchange | NL0012661870 ISIN |
DE Country | 74 Employees | - Last Dividend | - Last Split | - IPO Date |
InflaRx N.V. is a clinical-stage biopharmaceutical company based in Jena, Germany, with operations extending to the United States, focused on the discovery and development of inhibitors leveraging its proprietary C5a technology. Founded in 2007, originally as Fireman B.V., the company underwent a rebranding to InflaRx N.V. in 2017. It specializes in targeting C5a, a key inflammatory mediator implicated in a range of autoimmune and inflammatory diseases. InflaRx's innovative approach aims to mitigate the progression of these diseases by inhibiting the action of C5a. The company engages in significant collaborations, including a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc., underscoring its commitment to advancing its pipeline of treatments through strategic partnerships.
An intravenously administered first-in-class anti-C5a monoclonal antibody. Vilobelimab has completed a Phase III clinical trial for the treatment of hidradenitis suppurativa, a chronic inflammatory skin disease. It is also undergoing Phase II trials for anti-neutrophil cytoplasm antibody-associated vasculitis, a severe autoimmune disease; a Phase IIa exploratory study for pyoderma gangraenosum, another chronic inflammatory skin disorder; and a Phase II trial for PD-1/PD-L1 inhibitor-resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma.
An oral, small molecule drug candidate designed for the management of chronic inflammatory and autoimmune diseases. Currently under development, INF904 represents InflaRx's efforts to expand its portfolio into oral therapeutics for wider applications in autoimmunity and inflammation.
This candidate is in the pre-clinical development stage and seeks to offer a new treatment option for chronic inflammation and autoimmune diseases. IFX002 illustrates InflaRx's commitment to diversifying its strategies against inflammatory mediators beyond its flagship C5a technology.
A specialized application of vilobelimab, targeting the treatment of COVID-19 and broader Acute Respiratory Distress Syndrome (ARDS). In this context, InflaRx aims to address the inflammatory component of these respiratory conditions, reflecting the company's adaptability in applying its technologies to emergent global health challenges.